Johnson & Johnson’s first-quarter results are in line with our expectations and we are confident we will achieve the full-year financial guidance we established at the beginning of the year. The pending acquisition of Actelion demonstrates our ongoing commitment to bringing innovation to patients with significant unmet needs, and provides a unique opportunity for us to expand our portfolio with leading, differentiated in-market medicines and promising late-stage products. We look forward to the associates from Actelion joining the Johnson & Johnson Family of Companies.”

**WORLDWIDE CONSUMER SALES**

$3.2B

Consumer worldwide sales increase: 1.0%

Primary contributors to growth:

- **Contact lenses**
  - Acuvue®
  - Oasys®
  - NeoStrata®
  - Motrin®

**WORLDWIDE PHARMACEUTICAL SALES**

$8.2B

Pharmaceutical worldwide sales increase: 0.8%

Primary contributors to growth:

- **Dilaudid**
  - Imbruvica®
  - Stelara®
  - Insignia®

**WORLDWIDE MEDICAL DEVICES SALES**

$6.3B

Medical Devices worldwide sales increase: 3.0%

Primary contributors to growth:

- Electrophysiology
- Acuvue® Contact lenses
- Endoscopes
- Surgical Vision
- Wound Closure


*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-Looking Statements” included in the Johnson & Johnson’s earnings release issued on April 18, 2017, as well as the Johnson & Johnson Annual Report on Form 10-K for the fiscal year ended January 1, 2017. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.